Skip to content

Study · Animal study (in vivo) · mouse · 2022

14 results

The protective effects of S14G-humanin on gestational diabetes mellitus symptoms.

Jiang H, Xu Y, Cao L

Gynecological endocrinology : the official journal of the International Society of Gynecological Endocrinology10 May 2022Cited by 2 (Europe PMC)

PMID35536048 (opens in a new tab)DOI10.1080/09513590.2022.2073348 (opens in a new tab)PepBankPUB-35536048
Publisher pagePubMedAsk about this study
Jump to 14 results

Summary

The text of this summary is not shown here, because the article license does not allow reuse. Read it at the source (opens in a new tab)

Text rights: Publisher copyright. Results still quote short attributed sentences.

Results from this study14

14 results from studies that gave the peptide. No result from this study comes from people.

  1. 01AnimalAnimal study (in vivo)Efficacy outcome

    In mice with diabetes mellitus, S14G-humanin reduced blood glucose levels.

    In plain wordsIn diabetic mice, S14G-humanin lowered blood glucose.

    Peptide
    Humanin
    Outcome
    DecreaseBlood glucose
    Study

    mousen: not reported in source

    mice with diabetes mellitus (maternal and neonatal outcomes)
    Outcome group
    Glycemic control · Metabolic and weight
    Studied dose
    Dose not stated

    Source sentences

    Summary
    The results show that S14G-humanin administration reduced the blood glucose levels and elevated the serum insulin levels in diabetes mellitus mice.
    1 context sentence
    Summary · context
    Here, we investigated the protective effects of S14G-humanin, a potent humanin analogue, against maternal and neonatal adverse outcomes in mice with diabetes mellitus.
  2. 02AnimalAnimal study (in vivo)Efficacy outcome

    In mice with diabetes mellitus, S14G-humanin elevated serum insulin levels.

    In plain wordsIn diabetic mice, S14G-humanin raised serum insulin.

    Peptide
    Humanin
    Outcome
    IncreaseSerum insulin
    Study

    mousen: not reported in source

    mice with diabetes mellitus (maternal and neonatal outcomes)
    Outcome group
    Glycemic control · Metabolic and weight
    Studied dose
    Dose not stated

    Source sentences

    Summary
    The results show that S14G-humanin administration reduced the blood glucose levels and elevated the serum insulin levels in diabetes mellitus mice.
    1 context sentence
    Summary · context
    Here, we investigated the protective effects of S14G-humanin, a potent humanin analogue, against maternal and neonatal adverse outcomes in mice with diabetes mellitus.
  3. 03AnimalAnimal study (in vivo)Efficacy outcome

    In mice with diabetes mellitus, S14G-humanin decreased low-density lipoprotein.

    In plain wordsIn diabetic mice, S14G-humanin lowered LDL cholesterol.

    Peptide
    Humanin
    Outcome
    DecreaseLow-density lipoprotein
    Study

    mousen: not reported in source

    mice with diabetes mellitus (maternal and neonatal outcomes)
    Outcome group
    Lipids · Metabolic and weight
    Studied dose
    Dose not stated

    Source sentences

    Summary
    The parameters of serum lipid metabolism including low-density lipoprotein, total cholesterol, and high-density lipoprotein in diabetes mellitus mice were also decreased after S14G-humanin administration.
    1 context sentence
    Summary · context
    Here, we investigated the protective effects of S14G-humanin, a potent humanin analogue, against maternal and neonatal adverse outcomes in mice with diabetes mellitus.
  4. 04AnimalAnimal study (in vivo)Efficacy outcome

    In mice with diabetes mellitus, S14G-humanin decreased total cholesterol.

    In plain wordsIn diabetic mice, S14G-humanin lowered total cholesterol.

    Peptide
    Humanin
    Outcome
    DecreaseTotal cholesterol
    Study

    mousen: not reported in source

    mice with diabetes mellitus (maternal and neonatal outcomes)
    Outcome group
    Lipids · Metabolic and weight
    Studied dose
    Dose not stated

    Source sentences

    Summary
    The parameters of serum lipid metabolism including low-density lipoprotein, total cholesterol, and high-density lipoprotein in diabetes mellitus mice were also decreased after S14G-humanin administration.
    1 context sentence
    Summary · context
    Here, we investigated the protective effects of S14G-humanin, a potent humanin analogue, against maternal and neonatal adverse outcomes in mice with diabetes mellitus.
  5. 05AnimalAnimal study (in vivo)Efficacy outcome

    In mice with diabetes mellitus, S14G-humanin decreased high-density lipoprotein.

    In plain wordsIn diabetic mice, S14G-humanin lowered HDL cholesterol.

    Peptide
    Humanin
    Outcome
    DecreaseHigh-density lipoprotein
    Study

    mousen: not reported in source

    mice with diabetes mellitus (maternal and neonatal outcomes)
    Outcome group
    Lipids · Metabolic and weight
    Studied dose
    Dose not stated

    Source sentences

    Summary
    The parameters of serum lipid metabolism including low-density lipoprotein, total cholesterol, and high-density lipoprotein in diabetes mellitus mice were also decreased after S14G-humanin administration.
    1 context sentence
    Summary · context
    Here, we investigated the protective effects of S14G-humanin, a potent humanin analogue, against maternal and neonatal adverse outcomes in mice with diabetes mellitus.
  6. 06AnimalAnimal study (in vivo)Efficacy outcome

    In mice with diabetes mellitus, S14G-humanin increased the fetus alive ratio.

    In plain wordsIn diabetic mice, S14G-humanin raised the share of live fetuses.

    Peptide
    Humanin
    Outcome
    IncreaseFetus alive ratio
    Study

    mousen: not reported in source

    mice with diabetes mellitus (maternal and neonatal outcomes)
    Outcome group
    Pregnancy and fetal development · Reproductive and sexual health
    Studied dose
    Dose not stated

    Source sentences

    Summary
    Intervention with S14G-humanin also increased the fetus alive ratio and fetal length, as well as decreased fetal and placenta weights.
    1 context sentence
    Summary · context
    Here, we investigated the protective effects of S14G-humanin, a potent humanin analogue, against maternal and neonatal adverse outcomes in mice with diabetes mellitus.
  7. 07AnimalAnimal study (in vivo)Efficacy outcome

    In mice with diabetes mellitus, S14G-humanin increased fetal length.

    In plain wordsIn diabetic mice, S14G-humanin increased fetal length.

    Peptide
    Humanin
    Outcome
    IncreaseFetal length
    Study

    mousen: not reported in source

    mice with diabetes mellitus (maternal and neonatal outcomes)
    Outcome group
    Pregnancy and fetal development · Reproductive and sexual health
    Studied dose
    Dose not stated

    Source sentences

    Summary
    Intervention with S14G-humanin also increased the fetus alive ratio and fetal length, as well as decreased fetal and placenta weights.
    1 context sentence
    Summary · context
    Here, we investigated the protective effects of S14G-humanin, a potent humanin analogue, against maternal and neonatal adverse outcomes in mice with diabetes mellitus.
  8. 08AnimalAnimal study (in vivo)Efficacy outcome

    In mice with diabetes mellitus, S14G-humanin decreased fetal weight.

    In plain wordsIn diabetic mice, S14G-humanin lowered fetal weight.

    Peptide
    Humanin
    Outcome
    DecreaseFetal weight
    Study

    mousen: not reported in source

    mice with diabetes mellitus (maternal and neonatal outcomes)
    Outcome group
    Pregnancy and fetal development · Reproductive and sexual health
    Studied dose
    Dose not stated

    Source sentences

    Summary
    Intervention with S14G-humanin also increased the fetus alive ratio and fetal length, as well as decreased fetal and placenta weights.
    1 context sentence
    Summary · context
    Here, we investigated the protective effects of S14G-humanin, a potent humanin analogue, against maternal and neonatal adverse outcomes in mice with diabetes mellitus.
  9. 09AnimalAnimal study (in vivo)Efficacy outcome

    In mice with diabetes mellitus, S14G-humanin decreased placenta weight.

    In plain wordsIn diabetic mice, S14G-humanin lowered placenta weight.

    Peptide
    Humanin
    Outcome
    DecreasePlacenta weight
    Study

    mousen: not reported in source

    mice with diabetes mellitus (maternal and neonatal outcomes)
    Outcome group
    Pregnancy and fetal development · Reproductive and sexual health
    Studied dose
    Dose not stated

    Source sentences

    Summary
    Intervention with S14G-humanin also increased the fetus alive ratio and fetal length, as well as decreased fetal and placenta weights.
    1 context sentence
    Summary · context
    Here, we investigated the protective effects of S14G-humanin, a potent humanin analogue, against maternal and neonatal adverse outcomes in mice with diabetes mellitus.
  10. 10AnimalAnimal study (in vivo)Efficacy outcome

    In the placentas of mice with diabetes mellitus, S14G-humanin elevated catalase activity.

    In plain wordsIn diabetic mice, S14G-humanin raised catalase activity in the placenta.

    Peptide
    Humanin
    Outcome
    IncreasePlacental catalase activity
    Study

    mousen: not reported in source

    mice with diabetes mellitus (maternal and neonatal outcomes)
    Outcome group
    Oxidative stress · Reproductive and sexual health
    Studied dose
    Dose not stated

    Source sentences

    Summary
    In addition, we demonstrate that S14G-humanin elevated the activity of the anti-oxidative enzymes catalase, glutathione peroxidase, and superoxide dismutase and reduced the inflammatory cytokines levels in the placentas of diabetes mellitus mice.
    1 context sentence
    Summary · context
    Here, we investigated the protective effects of S14G-humanin, a potent humanin analogue, against maternal and neonatal adverse outcomes in mice with diabetes mellitus.
  11. 11AnimalAnimal study (in vivo)Efficacy outcome

    In the placentas of mice with diabetes mellitus, S14G-humanin elevated glutathione peroxidase activity.

    In plain wordsIn diabetic mice, S14G-humanin raised glutathione peroxidase activity in the placenta.

    Peptide
    Humanin
    Outcome
    IncreasePlacental glutathione peroxidase activity
    Study

    mousen: not reported in source

    mice with diabetes mellitus (maternal and neonatal outcomes)
    Outcome group
    Oxidative stress · Reproductive and sexual health
    Studied dose
    Dose not stated

    Source sentences

    Summary
    In addition, we demonstrate that S14G-humanin elevated the activity of the anti-oxidative enzymes catalase, glutathione peroxidase, and superoxide dismutase and reduced the inflammatory cytokines levels in the placentas of diabetes mellitus mice.
    1 context sentence
    Summary · context
    Here, we investigated the protective effects of S14G-humanin, a potent humanin analogue, against maternal and neonatal adverse outcomes in mice with diabetes mellitus.
  12. 12AnimalAnimal study (in vivo)Efficacy outcome

    In the placentas of mice with diabetes mellitus, S14G-humanin elevated superoxide dismutase activity.

    In plain wordsIn diabetic mice, S14G-humanin raised superoxide dismutase activity in the placenta.

    Peptide
    Humanin
    Outcome
    IncreasePlacental superoxide dismutase activity
    Study

    mousen: not reported in source

    mice with diabetes mellitus (maternal and neonatal outcomes)
    Outcome group
    Oxidative stress · Reproductive and sexual health
    Studied dose
    Dose not stated

    Source sentences

    Summary
    In addition, we demonstrate that S14G-humanin elevated the activity of the anti-oxidative enzymes catalase, glutathione peroxidase, and superoxide dismutase and reduced the inflammatory cytokines levels in the placentas of diabetes mellitus mice.
    1 context sentence
    Summary · context
    Here, we investigated the protective effects of S14G-humanin, a potent humanin analogue, against maternal and neonatal adverse outcomes in mice with diabetes mellitus.
  13. 13AnimalAnimal study (in vivo)Efficacy outcome

    In the placentas of mice with diabetes mellitus, S14G-humanin reduced inflammatory cytokine levels.

    In plain wordsIn diabetic mice, S14G-humanin lowered inflammatory cytokines in the placenta.

    Peptide
    Humanin
    Outcome
    DecreasePlacental inflammatory cytokines
    Study

    mousen: not reported in source

    mice with diabetes mellitus (maternal and neonatal outcomes)
    Outcome group
    Inflammation markers · Immune and inflammation
    Studied dose
    Dose not stated

    Source sentences

    Summary
    In addition, we demonstrate that S14G-humanin elevated the activity of the anti-oxidative enzymes catalase, glutathione peroxidase, and superoxide dismutase and reduced the inflammatory cytokines levels in the placentas of diabetes mellitus mice.
    1 context sentence
    Summary · context
    Here, we investigated the protective effects of S14G-humanin, a potent humanin analogue, against maternal and neonatal adverse outcomes in mice with diabetes mellitus.
  14. 14AnimalAnimal study (in vivo)Efficacy outcome

    In the placentas of mice with diabetes mellitus, S14G-humanin attenuated the increased endoplasmic reticulum stress.

    In plain wordsIn diabetic mice, S14G-humanin reduced stress in the placenta's endoplasmic reticulum.

    Peptide
    Humanin
    Outcome
    DecreasePlacental endoplasmic reticulum stress
    Study

    mousen: not reported in source

    mice with diabetes mellitus (maternal and neonatal outcomes)
    Outcome group
    Oxidative stress · Reproductive and sexual health
    Studied dose
    Dose not stated

    Source sentences

    Summary
    The significantly increased endoplasmic reticulum stress in the placentas of diabetes mellitus mice was also attenuated by S14G-humanin administration.
    1 context sentence
    Summary · context
    Here, we investigated the protective effects of S14G-humanin, a potent humanin analogue, against maternal and neonatal adverse outcomes in mice with diabetes mellitus.

AI wrote and checked these results. AI can make mistakes, so check important results against the source.

Version history

PepBank keeps every version of the data on this study. Status changes from Retraction Watch, Europe PMC and Crossref are listed with their source.

  1. Version 2Current

    13 Oct 2026, 21:44 UTC

    Study results updated

  2. Version 1

    13 Oct 2026, 16:31 UTC

    First added · source update from Europe PMC

Subjects

Terms as the source lists them.

Publication types

PepBank is a research reference. Talk to a doctor before you use any peptide.